Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aquestive ...

The market expects Aquestive Therapeutics (AQST) to deliver a year-over-year increase in earnings on higher revenues when it ...

Levi & Korsinsky, LLP alerts investors in Aquestive Therapeutics, Inc. (NASDAQ: AQST) that Daniel Barber, the Company's Chief Executive Officer, President, and Director, is named as an individual ...

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance ...

Based on the one-year price targets offered by 9 analysts, the average target price for Aquestive Therapeutics Inc (NASDAQ:AQST) is $9.22 with a high estimate of $12.00 and a low estimate of $6.00.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Aquestive Therapeutics (AQST) is a stock that can certainly grab ...

A webcast of the presentation at the H.C. Wainwright 26th Annual Global Investment Conference will be available on the "Events and Presentation" page of the Investors section of the Company's website.

Aquestive Therapeutics’ oral epinephrine film has cleared another hurdle on its path to a pivotal clinical trial, holding its own against the intramuscular injection incumbent in a study of healthy ...

On Friday, Aquestive Therapeutics, Inc. (NASDAQ:AQST) hosted a virtual investor day highlighting the company’s Anaphylm (epinephrine) Sublingual Film and AQST-108 (epinephrine) Topical Gel. Aquestive ...